Eplerenon Vivanta: Uses, Dosage & Side Effects
A selective mineralocorticoid receptor antagonist (aldosterone blocker) used for heart failure after myocardial infarction and as adjunctive therapy for essential hypertension
Eplerenon Vivanta (eplerenone) is a prescription selective mineralocorticoid receptor antagonist used to reduce the risk of cardiovascular mortality and morbidity in patients with heart failure following a myocardial infarction (heart attack), and as add-on therapy for essential hypertension. It works by blocking the mineralocorticoid receptor, thereby inhibiting the harmful effects of excess aldosterone on the heart, blood vessels, and kidneys. Unlike the older aldosterone antagonist spironolactone, eplerenone has high selectivity for the mineralocorticoid receptor and minimal activity at androgen and progesterone receptors, resulting in fewer hormonal side effects. Eplerenon Vivanta is available as 25 mg film-coated tablets for oral use.
Quick Facts: Eplerenon Vivanta
Key Takeaways
- Eplerenon Vivanta (eplerenone) is a selective mineralocorticoid receptor antagonist (MRA) that blocks the harmful effects of aldosterone on the heart, blood vessels, and kidneys, reducing cardiac fibrosis and remodeling after heart failure.
- It is approved for reducing cardiovascular mortality in patients with heart failure and left ventricular dysfunction following myocardial infarction (EPHESUS trial), and for chronic heart failure with reduced ejection fraction (EMPHASIS-HF trial).
- Compared to spironolactone, eplerenone has significantly fewer sex hormone-related side effects (gynecomastia, breast tenderness) due to its high selectivity for the mineralocorticoid receptor.
- Regular monitoring of serum potassium and renal function is essential, as eplerenone can cause hyperkalemia (elevated potassium) which may lead to dangerous cardiac arrhythmias.
- The typical starting dose is 25 mg once daily, which may be increased to 50 mg once daily based on tolerability and potassium levels. It should not be combined with potassium-sparing diuretics or strong CYP3A4 inhibitors.
What Is Eplerenon Vivanta and What Is It Used For?
Eplerenon Vivanta contains the active substance eplerenone, a selective mineralocorticoid receptor antagonist (MRA) belonging to the pharmacological class of potassium-sparing diuretics and aldosterone antagonists (ATC code: C03DA04). Eplerenone was developed as a more selective alternative to spironolactone, the first-generation aldosterone antagonist that has been used in clinical practice since the 1960s. While spironolactone remains an important medication, its lack of selectivity for the mineralocorticoid receptor means it also binds to androgen and progesterone receptors, causing side effects such as gynecomastia in men, breast pain, and menstrual irregularities in women. Eplerenone was specifically designed to retain the beneficial aldosterone-blocking properties while minimizing these hormone-related adverse effects.
Aldosterone is a steroid hormone produced by the adrenal glands as part of the renin-angiotensin-aldosterone system (RAAS). Under normal physiological conditions, aldosterone plays a crucial role in maintaining sodium and potassium balance, blood volume, and blood pressure by acting on the mineralocorticoid receptors in the kidneys, promoting sodium and water reabsorption while facilitating potassium excretion. However, in pathological states such as heart failure, the RAAS becomes chronically overactivated, leading to persistently elevated aldosterone levels. This chronic aldosterone excess has devastating consequences for the cardiovascular system that extend far beyond simple fluid retention.
Excess aldosterone drives myocardial fibrosis, the pathological accumulation of collagen and scar tissue in the heart muscle that impairs cardiac function and promotes arrhythmias. It causes endothelial dysfunction, reducing the ability of blood vessels to dilate properly and increasing vascular stiffness. Aldosterone promotes inflammation within the vascular wall, accelerates atherosclerosis, and contributes to left ventricular hypertrophy (abnormal thickening of the heart muscle). In the kidneys, excess aldosterone causes glomerular damage and promotes proteinuria (protein loss in urine). Importantly, these harmful effects of aldosterone are not fully blocked by ACE inhibitors or angiotensin receptor blockers (ARBs) alone, a phenomenon known as "aldosterone escape" or "aldosterone breakthrough," which occurs in up to 40% of patients treated with these agents.
By selectively blocking the mineralocorticoid receptor, eplerenone prevents aldosterone from binding and exerting these harmful effects. This results in reduced myocardial fibrosis, improved endothelial function, decreased inflammation, reduced ventricular remodeling, and modest diuresis with blood pressure reduction. The clinical significance of these benefits has been established in two landmark randomized controlled trials:
- EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study): This pivotal trial enrolled 6,632 patients with left ventricular dysfunction (LVEF ≤40%) and heart failure symptoms or diabetes following acute myocardial infarction. Patients were randomized to eplerenone (25 mg initially, titrated to 50 mg daily) or placebo, in addition to optimal medical therapy. Over a mean follow-up of 16 months, eplerenone reduced all-cause mortality by 15% (relative risk reduction; p=0.008), cardiovascular mortality by 17%, and the composite of cardiovascular death or cardiovascular hospitalization by 13%. The benefit was observed as early as 30 days after randomization.
- EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure): This trial enrolled 2,737 patients with chronic systolic heart failure (LVEF ≤35%) and mild symptoms (NYHA class II). Eplerenone reduced the primary composite endpoint of cardiovascular death or heart failure hospitalization by 37% (hazard ratio 0.63; p<0.001). All-cause mortality was reduced by 24%. The trial was stopped early due to the overwhelming benefit of eplerenone. This trial established that MRAs provide significant survival benefits even in patients with mild heart failure symptoms.
Based on this robust evidence, eplerenone is recommended as a Class I (strongest recommendation) therapy in both the European Society of Cardiology (ESC) 2023 Heart Failure Guidelines and the American College of Cardiology/American Heart Association (ACC/AHA) guidelines for patients with heart failure with reduced ejection fraction (HFrEF). It is considered one of the four pillars of guideline-directed medical therapy (GDMT) for HFrEF, alongside ACE inhibitors/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors.
In addition to heart failure, eplerenone is approved as add-on therapy for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled with other antihypertensive agents. Clinical studies have demonstrated that eplerenone reduces systolic blood pressure by approximately 8–12 mmHg and diastolic blood pressure by 4–6 mmHg when used as monotherapy, with additional reductions when combined with other antihypertensive drugs. The blood pressure-lowering effect becomes apparent within 2 weeks and reaches its maximum at approximately 4 weeks.
Current international guidelines recommend four classes of medication for patients with heart failure with reduced ejection fraction (HFrEF): (1) ACE inhibitor, ARB, or ARNI (sacubitril/valsartan), (2) beta-blocker (bisoprolol, carvedilol, or metoprolol succinate), (3) mineralocorticoid receptor antagonist such as eplerenone, and (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). Together, these four drug classes provide complementary neurohormonal blockade and have been shown to reduce mortality and hospitalization in heart failure.
What Should You Know Before Taking Eplerenon Vivanta?
Contraindications
Eplerenone must not be used in the following situations, as the risks clearly outweigh any potential benefit:
- Hypersensitivity: Known allergy to eplerenone or any of the excipients in the formulation (lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium laurilsulfate, talc, magnesium stearate, titanium dioxide, macrogol, iron oxide yellow, iron oxide red, polysorbate 80).
- Serum potassium >5.0 mmol/L at initiation: Since eplerenone raises potassium levels, starting treatment in patients who already have elevated potassium creates an unacceptable risk of life-threatening hyperkalemia.
- Severe renal impairment: Estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m². The reduced ability of the kidneys to excrete potassium significantly increases the risk of hyperkalemia.
- Severe hepatic impairment: Child-Pugh class C. Eplerenone is metabolized by the liver, and severe hepatic dysfunction leads to unpredictable drug exposure.
- Concomitant use with potassium-sparing diuretics: Spironolactone, triamterene, or amiloride. The combination produces an additive potassium-retaining effect with high risk of dangerous hyperkalemia.
- Concomitant use with strong CYP3A4 inhibitors: Ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, telithromycin, and nefazodone. These drugs dramatically increase eplerenone plasma concentrations (up to 5-fold with ketoconazole), leading to exaggerated pharmacological effects and hyperkalemia.
- Combination of ACE inhibitor and ARB with eplerenone: The triple combination of eplerenone with both an ACE inhibitor and an ARB is contraindicated due to excessive RAAS blockade and an unacceptable risk of hyperkalemia, hypotension, and renal impairment.
Warnings and Precautions
Eplerenone can cause potentially life-threatening hyperkalemia (elevated serum potassium). Serum potassium and renal function must be measured before starting treatment, within the first week, at one month, and periodically thereafter (at least every 3 months). If potassium exceeds 5.5 mmol/L, the dose must be reduced or treatment discontinued. The risk is highest in elderly patients, those with diabetes, and those with renal impairment.
Special caution is required in the following clinical situations:
- Impaired renal function (eGFR 30–59 mL/min): Eplerenone can be used with caution in moderate renal impairment, but requires more frequent potassium monitoring (every 1–2 weeks during the first month and after dose adjustment). If eGFR falls below 30 mL/min during treatment, eplerenone must be discontinued.
- Diabetes mellitus: Patients with diabetes are at particularly high risk of hyperkalemia due to the effects of insulin deficiency and diabetic nephropathy on potassium handling. In the EPHESUS trial, patients with diabetes had a significantly higher incidence of hyperkalemia. More frequent potassium monitoring is recommended in diabetic patients.
- Elderly patients: Age-related decline in renal function increases the risk of hyperkalemia. No dose adjustment is required solely based on age, but renal function and potassium should be monitored closely.
- Mild to moderate hepatic impairment: No dose adjustment is needed, as studies in patients with Child-Pugh class A and B cirrhosis showed no significant increase in eplerenone exposure. However, monitoring is advisable.
- Concomitant ACE inhibitor or ARB use: Most patients taking eplerenone for heart failure will also be on an ACE inhibitor or ARB. This combination is standard and guideline-recommended, but it increases the risk of hyperkalemia compared to either drug alone. Careful potassium monitoring is essential.
Pregnancy and Breastfeeding
There are no adequate and well-controlled studies of eplerenone in pregnant women. Animal reproductive toxicity studies have not revealed direct harmful effects on embryo-fetal development. However, as a precaution, eplerenone should not be used during pregnancy unless the potential benefit to the mother clearly justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment with eplerenone.
It is unknown whether eplerenone or its metabolites are excreted in human breast milk. In animal studies, eplerenone and its metabolites were detected in rat milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue eplerenone, taking into account the importance of the drug to the mother. Breastfeeding is generally not recommended during treatment with eplerenone.
Driving and Operating Machinery
The effects of eplerenone on the ability to drive and use machines have not been specifically studied. Eplerenone is not expected to impair driving ability based on its pharmacological profile. However, dizziness has been reported as a side effect, particularly at the start of treatment or after dose increases. If dizziness occurs, patients should avoid driving or operating heavy machinery until the symptoms resolve.
How Does Eplerenon Vivanta Interact with Other Drugs?
Understanding eplerenone's drug interactions is essential for safe prescribing. Eplerenone is metabolized predominantly by the hepatic cytochrome P450 enzyme CYP3A4. Unlike fremanezumab and other monoclonal antibodies, eplerenone is a small molecule that undergoes extensive hepatic metabolism, making it vulnerable to pharmacokinetic drug interactions with CYP3A4 inhibitors and inducers. Additionally, as a potassium-retaining agent, eplerenone has important pharmacodynamic interactions with other drugs that affect serum potassium levels.
Major Interactions (Contraindicated or Avoid)
| Drug / Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Ketoconazole, itraconazole | Strong CYP3A4 inhibition | Up to 5-fold increase in eplerenone exposure | Contraindicated |
| Ritonavir, nelfinavir | Strong CYP3A4 inhibition | Markedly increased eplerenone levels | Contraindicated |
| Clarithromycin, telithromycin | Strong CYP3A4 inhibition | Significantly increased eplerenone levels | Contraindicated |
| Spironolactone, triamterene, amiloride | Additive potassium retention | Severe hyperkalemia | Contraindicated |
| Potassium supplements (KCl) | Additive potassium load | Hyperkalemia | Avoid unless hypokalemic |
Moderate Interactions (Use with Caution)
| Drug / Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Erythromycin, verapamil, diltiazem, fluconazole | Moderate CYP3A4 inhibition | Up to 2–3 fold increase in eplerenone | Max dose 25 mg/day |
| ACE inhibitors (ramipril, enalapril) | RAAS blockade + potassium retention | Increased hyperkalemia risk | Standard combination; monitor K+ |
| ARBs (losartan, valsartan, candesartan) | RAAS blockade + potassium retention | Increased hyperkalemia risk | Standard combination; monitor K+ |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Reduced renal prostaglandin synthesis | Hyperkalemia, reduced renal function, reduced antihypertensive effect | Use with caution; monitor renal function and K+ |
| Lithium | Reduced renal lithium clearance | Lithium toxicity | Monitor lithium levels closely |
| Ciclosporin, tacrolimus | Nephrotoxicity + potassium retention | Hyperkalemia, renal impairment | Avoid combination; if necessary, monitor closely |
| Trimethoprim (co-trimoxazole) | Blocks renal potassium excretion | Hyperkalemia | Monitor K+ within 3 days of initiation |
| Rifampicin, St. John’s Wort, phenytoin, carbamazepine | CYP3A4 induction | Reduced eplerenone efficacy | Avoid; if necessary, consider higher monitoring |
Grapefruit juice is a moderate CYP3A4 inhibitor and can increase eplerenone plasma levels by approximately 25%. While this increase is modest, patients should be advised to avoid regular or excessive consumption of grapefruit or grapefruit juice during eplerenone therapy, particularly if they are also taking other CYP3A4 inhibitors or have risk factors for hyperkalemia.
Importantly, eplerenone does not significantly inhibit or induce CYP3A4 or other major CYP enzymes at therapeutic concentrations, so it is unlikely to affect the metabolism of other drugs. Eplerenone does not affect the pharmacokinetics of digoxin, warfarin, or oral contraceptives based on interaction studies.
What Is the Correct Dosage of Eplerenon Vivanta?
Adults – Heart Failure after Myocardial Infarction
Heart Failure Post-MI (LVEF ≤40%)
Treatment should be initiated between 3 and 14 days after the acute myocardial infarction in clinically stable patients:
- Starting dose: 25 mg once daily
- Target dose: Increase to 50 mg once daily after 4 weeks, provided serum potassium is ≤5.0 mmol/L and renal function is stable
- Maximum dose: 50 mg once daily
Chronic Heart Failure (NYHA Class II, LVEF ≤35%)
- Starting dose: 25 mg once daily
- Target dose: 50 mg once daily after 4 weeks if potassium is ≤5.0 mmol/L
- Maximum dose: 50 mg once daily
Essential Hypertension (Add-on Therapy)
- Starting dose: 50 mg once daily
- If inadequate response after 4 weeks: May increase to 50 mg twice daily (maximum 100 mg/day in some regions)
- Note: Higher doses are not recommended in heart failure patients
Dose Adjustment Based on Potassium Levels
| Serum Potassium Level | Action Required |
|---|---|
| <5.0 mmol/L | Increase dose from 25 mg to 50 mg daily (if on 25 mg); maintain current dose (if on 50 mg) |
| 5.0–5.4 mmol/L | No dose change. Continue current dose and recheck within 1 week |
| 5.5–5.9 mmol/L | Decrease dose from 50 mg to 25 mg daily; if already on 25 mg, withhold eplerenone |
| ≥6.0 mmol/L | Withhold eplerenone immediately. Recheck potassium. May restart at 25 mg every other day once potassium is <5.0 mmol/L |
Children and Adolescents
Eplerenone is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of eplerenone have not been established in this population. There are no adequate pediatric clinical data available. If treatment with a mineralocorticoid receptor antagonist is required in a pediatric patient, specialist guidance should be sought.
Elderly Patients
No dose adjustment is required solely on the basis of age. However, elderly patients are more likely to have reduced renal function and are at higher risk of hyperkalemia. Renal function (eGFR) and serum potassium should be assessed before starting treatment and monitored more frequently during treatment. The dose titration schedule should be followed carefully, with particular attention to potassium levels at each step.
Renal Impairment
No dose adjustment is required for patients with mild renal impairment (eGFR ≥60 mL/min). In patients with moderate renal impairment (eGFR 30–59 mL/min), treatment should be initiated at 25 mg every other day, with careful potassium monitoring. Eplerenone is contraindicated in severe renal impairment (eGFR <30 mL/min). Potassium levels should be checked within 1 week of starting therapy or after any dose change, and at least monthly thereafter in patients with renal impairment.
Missed Dose
If you miss a dose of Eplerenon Vivanta, take it as soon as you remember, provided it is not close to the time of your next scheduled dose. If it is nearly time for your next dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a missed dose. Taking a double dose increases the risk of hypotension and hyperkalemia.
Overdose
No cases of human overdose with eplerenone have been reported to date. The most likely clinical manifestation of overdose would be hypotension (low blood pressure) and hyperkalemia (elevated potassium). Eplerenone is not removed by hemodialysis. In the event of suspected overdose, seek immediate medical attention. Treatment is supportive and symptomatic: hyperkalemia should be treated with standard measures (insulin and glucose, calcium gluconate, sodium bicarbonate, loop diuretics, or sodium polystyrene sulfonate as appropriate), and hypotension should be managed with intravenous fluids and, if necessary, vasopressors.
What Are the Side Effects of Eplerenon Vivanta?
Like all medicines, Eplerenon Vivanta can cause side effects, although not everybody gets them. The side effect profile of eplerenone has been extensively characterized in the EPHESUS and EMPHASIS-HF clinical trials, which together enrolled more than 9,000 patients. The most clinically important adverse effect is hyperkalemia, which requires regular monitoring. The following side effects have been reported with eplerenone, organized by frequency:
Common
Affects 1 to 10 in every 100 patients
- Hyperkalemia (elevated serum potassium >5.5 mmol/L)
- Dizziness
- Hypotension (low blood pressure), including orthostatic hypotension
- Diarrhea
- Nausea
- Abnormal renal function (elevated creatinine)
- Cough
- Headache
Uncommon
Affects 1 to 10 in every 1,000 patients
- Hyponatremia (low sodium levels)
- Dehydration
- Insomnia
- Gynecomastia (breast enlargement in men)
- Fatigue, asthenia (weakness)
- Muscle spasms
- Back pain
- Pruritus (itching)
- Skin rash
- Increased sweating
- Elevated liver enzymes (ALT, GGT)
- Elevated blood urea nitrogen (BUN)
- Flatulence, vomiting
Rare
Affects 1 to 10 in every 10,000 patients
- Angioedema (swelling of the face, lips, tongue, or throat)
- Eosinophilia (elevated eosinophil count)
- Pyelonephritis (kidney infection)
- Pharyngitis
Not Known
Frequency cannot be estimated from the available data
- Hypersensitivity reactions
Contact your doctor or seek emergency medical care immediately if you experience: signs of severe hyperkalemia such as muscle weakness, slow or irregular heartbeat, nausea, or tingling/numbness; signs of angioedema including swelling of the face, lips, tongue, or throat with difficulty breathing or swallowing; or signs of a severe allergic reaction. If potassium exceeds 6.0 mmol/L, this is a medical emergency requiring urgent treatment.
In the EPHESUS trial, the incidence of serious hyperkalemia (potassium >6.0 mmol/L) was 5.5% in the eplerenone group compared with 3.9% in the placebo group. Risk factors for hyperkalemia included baseline renal impairment, diabetes mellitus, proteinuria, and concomitant use of ACE inhibitors. The incidence of severe hyperkalemia can be minimized by following the recommended dose titration schedule, monitoring potassium regularly, and adjusting the dose according to serum potassium levels as described in the dosage section.
An important clinical advantage of eplerenone compared with spironolactone is its lower incidence of sex hormone-related side effects. In the EPHESUS trial, gynecomastia or breast pain occurred in only 0.5% of male patients receiving eplerenone, compared with reported rates of 6–10% with spironolactone. This is because eplerenone has approximately 500-fold lower affinity for the androgen receptor and approximately 100-fold lower affinity for the progesterone receptor compared with spironolactone. For male patients who experience gynecomastia or breast pain with spironolactone, switching to eplerenone is a well-established clinical strategy.
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed above. You can also report side effects directly to your national adverse drug reaction reporting system, which helps to provide more information on the safety of this medicine.
How Should You Store Eplerenon Vivanta?
Proper storage of Eplerenon Vivanta is important to ensure the medication remains effective and safe throughout its shelf life. The following storage conditions should be observed:
- Temperature: Store at room temperature, not exceeding 30°C (86°F). Do not refrigerate or freeze.
- Moisture protection: Keep the tablets in the original blister packaging or container to protect from moisture. Do not transfer tablets to other containers unless they provide equivalent moisture protection.
- Light protection: Store in the original packaging to protect from light.
- Children: Keep out of the sight and reach of children. Store in a secure location, preferably in a locked medicine cabinet or a high shelf that children cannot access.
- Expiry date: Do not use Eplerenon Vivanta after the expiry date which is stated on the carton and blister pack after "EXP." The expiry date refers to the last day of that month.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
What Does Eplerenon Vivanta Contain?
Each film-coated tablet of Eplerenon Vivanta contains:
Active Substance
- Eplerenone: 25 mg per film-coated tablet
Tablet Core (Excipients)
- Lactose monohydrate – a filler/diluent that provides bulk to the tablet. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
- Microcrystalline cellulose – a filler and binder that gives structural integrity to the tablet
- Croscarmellose sodium – a disintegrant that helps the tablet break apart in the gastrointestinal tract for proper absorption
- Hypromellose – used as a binder in the tablet core
- Sodium laurilsulfate – a wetting agent that improves drug dissolution
- Talc – a glidant that improves powder flow during manufacturing
- Magnesium stearate – a lubricant that prevents the tablet from sticking to manufacturing equipment
Film Coating
- Hypromellose – forms the base of the film coating
- Titanium dioxide (E171) – a white colorant that also provides opacity
- Macrogol (polyethylene glycol) – a plasticizer that makes the coating flexible
- Iron oxide yellow (E172) – provides the characteristic tablet color
- Iron oxide red (E172) – provides the characteristic tablet color
- Polysorbate 80 – a surfactant used in the coating formulation
The 25 mg tablets are typically round, biconvex, film-coated tablets with a distinctive yellow to light orange color. The appearance may vary slightly between manufacturers and different generic formulations. Check the patient information leaflet included in your specific product for the exact description of your tablets.
Eplerenon Vivanta contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. Patients with rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Frequently Asked Questions
Both eplerenone and spironolactone are mineralocorticoid receptor antagonists (aldosterone blockers) used to treat heart failure and hypertension. The key difference is selectivity: eplerenone is highly selective for the mineralocorticoid receptor, while spironolactone also binds to androgen and progesterone receptors. This means spironolactone can cause sex hormone-related side effects such as gynecomastia (breast enlargement) in 6–10% of men, breast tenderness, and menstrual irregularities in women. Eplerenone causes gynecomastia in fewer than 1% of men. However, spironolactone is more potent (25 mg of spironolactone is roughly equivalent to 50 mg of eplerenone), has a longer track record, and is less expensive. Both drugs are recommended in heart failure guidelines, and the choice between them often depends on tolerability and individual patient factors.
Potassium levels and renal function should be checked: before starting eplerenone, within the first week of treatment, at one month, and then at least every 3 months during ongoing therapy. More frequent monitoring (every 1–2 weeks) is recommended in patients with diabetes, renal impairment, elderly patients, and those taking concomitant ACE inhibitors or ARBs. Additional monitoring is required after any dose change, if an interacting medication is started or stopped, or during intercurrent illness (particularly dehydration, vomiting, or diarrhea). If your potassium rises above 5.5 mmol/L, your doctor will likely reduce the dose or temporarily stop eplerenone.
There is no specific contraindication to moderate alcohol consumption while taking eplerenone. However, alcohol can lower blood pressure, and combining it with eplerenone may increase the risk of dizziness, lightheadedness, or fainting, especially when standing up quickly. Patients with heart failure are generally advised to limit or avoid alcohol, as it can worsen heart function. If you do drink alcohol, do so in moderation and be aware of the potential for additive blood pressure-lowering effects. Discuss your alcohol consumption with your doctor.
Yes, eplerenone can be taken with or without food. Food does not significantly affect the absorption or overall exposure of eplerenone. You may find it easier to remember to take your medication if you associate it with a regular daily activity such as breakfast or dinner. Take the tablet at approximately the same time each day, with a glass of water. The tablet should be swallowed whole and not crushed or chewed.
Muscle weakness, tingling or numbness in the extremities, slow or irregular heartbeat, nausea, and general malaise can be signs of hyperkalemia (dangerously high potassium levels). If you experience any of these symptoms, contact your doctor immediately or go to the nearest emergency department. Severe hyperkalemia (potassium >6.0 mmol/L) is a medical emergency that can cause fatal cardiac arrhythmias if not treated promptly. Do not take your next dose of eplerenone until you have spoken with a healthcare professional and had your potassium level checked.
Eplerenone is typically a long-term medication, particularly when prescribed for heart failure. In the landmark clinical trials, the mortality and hospitalization benefits were sustained over the entire study period and are expected to continue with ongoing treatment. Most cardiologists recommend continuing eplerenone indefinitely as part of guideline-directed medical therapy for heart failure, provided it remains tolerated and serum potassium stays within safe limits. Do not stop taking eplerenone without consulting your doctor, even if you feel well, as stopping abruptly could lead to worsening heart failure. For hypertension, the duration of treatment depends on your overall blood pressure management plan and should be determined by your doctor.
References
- Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction (EPHESUS). N Engl J Med. 2003;348(14):1309–1321. doi:10.1056/NEJMoa030207
- Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms (EMPHASIS-HF). N Engl J Med. 2011;364(1):11–21. doi:10.1056/NEJMoa1009492
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2023 Focused Update). Eur Heart J. 2023;44(37):3627–3639. doi:10.1093/eurheartj/ehad195
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421. doi:10.1016/j.jacc.2021.12.012
- European Medicines Agency. Eplerenone – Summary of Product Characteristics. EMA. Updated 2025.
- British National Formulary. Eplerenone. National Institute for Health and Care Excellence (NICE). Updated 2025.
- Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543–551. doi:10.1056/NEJMoa040135
- Kolkhof P, Barfacker L. Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125–T140. doi:10.1530/JOE-16-0600
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. WHO. 2023.
About Our Medical Team
This article was written by the iMedic Medical Editorial Team, a multidisciplinary group of licensed physicians, clinical pharmacologists, and medical writers specializing in evidence-based drug information. Our content is independently produced without pharmaceutical company funding or influence.
All medication articles follow a rigorous editorial process: initial drafting based on regulatory-approved product information (EMA SmPC, FDA label, BNF monograph), cross-referencing with landmark clinical trial data and current international guidelines (ESC, AHA/ACC, WHO), expert medical review, and regular updates to reflect new evidence. Our goal is to provide accurate, accessible, and clinically useful drug information for patients and healthcare professionals worldwide.